Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients

Figure 1 Consort flow chart of subject deposition. MAFLD: Metabolic dysfunction-associated fatty liver disease; UDCA: Ursodeoxycholic acid.

Figure 2 Summary of patients achieving alanine aminotransferase normalization at week 12. ALT: Alanine aminotransferase; norUDCA: Norursodeoxycholic acid.

Figure 3 Summary of patients showing improvements in fibrosis. A: At week 12; B: At week 24. norUDCA: Norursodeoxycholic acid.

Figure 4 Mean reductions from baseline to end of treatment in nonalcoholic fatty liver disease fibrosis scores. NFS: Nonalcoholic fatty liver disease fibrosis; norUDCA: Norursodeoxycholic acid.

Figure 5 Mean reductions in lipid profile and glycosylated hemoglobin at baseline and end of the treatment. HbA1c: Glycosylated hemoglobin; norUDCA: Norursodeoxycholic acid; HDL: High-density lipoprotein; LDL: Low-density lipoprotein.